Literature DB >> 24681054

PAPNC, a novel method to calculate nucleotide diversity from large scale next generation sequencing data.

Wei Shao1, Mary F Kearney2, Valerie F Boltz2, Jonathan E Spindler2, John W Mellors3, Frank Maldarelli2, John M Coffin4.   

Abstract

Estimating viral diversity in infected patients can provide insight into pathogen evolution and emergence of drug resistance. With the widespread adoption of deep sequencing, it is important to develop tools to accurately calculate population diversity from very large datasets. Current methods for estimating diversity that are based on multiple alignments are not practical to apply to such data. In this study, the authors report a novel method (Pairwise Alignment Positional Nucleotide Counting, PAPNC) for estimating population diversity from 454 sequence data. The diversity measurements determined using this method were comparable to those calculated by average pairwise difference (APD) of multiply aligned sequences using MEGA5. Diversities were estimated for 9 patient plasma HIV samples sequenced with Titanium 454 technology and by single-genome sequencing (SGS). Diversities calculated from deep sequencing using PAPNC ranged from 0.002 to 0.021 while APD measurements calculated from SGS data ranged proximately from 0.001 to 0.018, with the difference being attributable to PCR error (contributing background diversity of 0.0016 in a control sample). Comparison of APDs estimated from 100 sets of sequences drawn at random from 454 generated data and from corresponding SGS data showed very close correlation between the two methods with R(2) of 0.96, and differing on average by about 1% (after correction for PCR error). The authors have developed a novel method that is good for calculating genetic diversities for large scale datasets from next generation sequencing. It can be implemented easily as a function in available variation calling programs like SAMtools or haplotype reconstruction software for nucleotide genetic diversity calculation. A Perl script implementing this method is available upon request.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HIV-1; Next generation sequencing; Viral population diversity calculation

Mesh:

Year:  2014        PMID: 24681054      PMCID: PMC4104926          DOI: 10.1016/j.jviromet.2014.03.008

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  26 in total

1.  Improvement in the accuracy of multiple sequence alignment program MAFFT.

Authors:  Kazutaka Katoh; Kei-ichi Kuma; Takashi Miyata; Hiroyuki Toh
Journal:  Genome Inform       Date:  2005

Review 2.  Multiple sequence alignment.

Authors:  Robert C Edgar; Serafim Batzoglou
Journal:  Curr Opin Struct Biol       Date:  2006-05-05       Impact factor: 6.809

3.  HIV-1 evolution and disease progression.

Authors:  M A Nowak; R M Anderson; M C Boerlijst; S Bonhoeffer; R M May; A J McMichael
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

4.  Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression.

Authors:  Ryan M Troyer; Kalonji R Collins; Awet Abraha; Erika Fraundorf; Dawn M Moore; Randall W Krizan; Zahra Toossi; Robert L Colebunders; Mark A Jensen; James I Mullins; Guido Vanham; Eric J Arts
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.

Authors:  J D Thompson; D G Higgins; T J Gibson
Journal:  Nucleic Acids Res       Date:  1994-11-11       Impact factor: 16.971

6.  Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.

Authors:  R Shankarappa; J B Margolick; S J Gange; A G Rodrigo; D Upchurch; H Farzadegan; P Gupta; C R Rinaldo; G H Learn; X He; X L Huang; J I Mullins
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.

Authors:  Sarah Palmer; Mary Kearney; Frank Maldarelli; Elias K Halvas; Christian J Bixby; Holly Bazmi; Diane Rock; Judith Falloon; Richard T Davey; Robin L Dewar; Julia A Metcalf; Scott Hammer; John W Mellors; John M Coffin
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

8.  SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors.

Authors:  Rodrigo Goya; Mark G F Sun; Ryan D Morin; Gillian Leung; Gavin Ha; Kimberley C Wiegand; Janine Senz; Anamaria Crisan; Marco A Marra; Martin Hirst; David Huntsman; Kevin P Murphy; Sam Aparicio; Sohrab P Shah
Journal:  Bioinformatics       Date:  2010-02-03       Impact factor: 6.937

9.  Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection.

Authors:  S M Wolinsky; B T Korber; A U Neumann; M Daniels; K J Kunstman; A J Whetsell; M R Furtado; Y Cao; D D Ho; J T Safrit
Journal:  Science       Date:  1996-04-26       Impact factor: 47.728

10.  The accuracy of several multiple sequence alignment programs for proteins.

Authors:  Paulo A S Nuin; Zhouzhi Wang; Elisabeth R M Tillier
Journal:  BMC Bioinformatics       Date:  2006-10-24       Impact factor: 3.169

View more
  8 in total

Review 1.  How can we better identify early HIV infections?

Authors:  Nora E Rosenberg; Christopher D Pilcher; Michael P Busch; Myron S Cohen
Journal:  Curr Opin HIV AIDS       Date:  2015-01       Impact factor: 4.283

2.  Environmental Viral Genomes Shed New Light on Virus-Host Interactions in the Ocean.

Authors:  Yosuke Nishimura; Hiroyasu Watai; Takashi Honda; Tomoko Mihara; Kimiho Omae; Simon Roux; Romain Blanc-Mathieu; Keigo Yamamoto; Pascal Hingamp; Yoshihiko Sako; Matthew B Sullivan; Susumu Goto; Hiroyuki Ogata; Takashi Yoshida
Journal:  mSphere       Date:  2017-03-01       Impact factor: 4.389

3.  Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals.

Authors:  Jan Weber; Richard M Gibson; Lenka Sácká; Dmytro Strunin; Jan Hodek; Jitka Weberová; Marcela Pávová; David J Alouani; Robert Asaad; Benigno Rodriguez; Michael M Lederman; Miguel E Quiñones-Mateu
Journal:  AIDS Res Ther       Date:  2017-03-20       Impact factor: 2.250

4.  Mistranslation can enhance fitness through purging of deleterious mutations.

Authors:  Sinisa Bratulic; Macarena Toll-Riera; Andreas Wagner
Journal:  Nat Commun       Date:  2017-05-19       Impact factor: 14.919

5.  High mutation rates limit evolutionary adaptation in Escherichia coli.

Authors:  Kathleen Sprouffske; José Aguilar-Rodríguez; Paul Sniegowski; Andreas Wagner
Journal:  PLoS Genet       Date:  2018-04-27       Impact factor: 5.917

6.  Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.

Authors:  Nicholas Silver; Mary Paynter; Georgina McAllister; Maureen Atchley; Christine Sayir; John Short; Dane Winner; David J Alouani; Freddie H Sharkey; Kicki Bergefall; Kate Templeton; David Carrington; Miguel E Quiñones-Mateu
Journal:  AIDS Res Ther       Date:  2018-11-08       Impact factor: 2.250

7.  Reduced and highly diverse peripheral HIV-1 reservoir in virally suppressed patients infected with non-B HIV-1 strains in Uganda.

Authors:  Samira Joussef-Piña; Immaculate Nankya; Sophie Nalukwago; Joy Baseke; Sandra Rwambuya; Dane Winner; Fred Kyeyune; Keith Chervenak; Bonnie Thiel; Robert Asaad; Curtis Dobrowolski; Benjamin Luttge; Blair Lawley; Cissy M Kityo; W Henry Boom; Jonathan Karn; Miguel E Quiñones-Mateu
Journal:  Retrovirology       Date:  2022-01-15       Impact factor: 4.602

8.  Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adults.

Authors:  Mary F Kearney; Jonathan Spindler; Ann Wiegand; Wei Shao; Richard Haubrich; Sharon Riddler; Christina M Lalama; Michael D Hughes; John M Coffin; John W Mellors
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.